LEX LOCALIS-JOURNAL OF LOCAL SELF-GOVERNMENT
ISSN:1581-5374 E-ISSN:1855-363X
VOL. 23, NO. S4(2025)

ARTIFICIAL INTELLIGENCE AND ROBOTICS IN PHARMACEUTICAL MANUFACTURING: LEGAL, BUSINESS, AND ENGINEERING CHALLENGES

Dr. Honey Gaur[1], Dr. Akshit Lamba[2],Dr. Swati Agrawal[3]

[1]Department of Civil Engineering, Structural Engineering concrete technology, transportation, GIS and remote sensing, sustainable materials, smart infrastructure using IoT, Kalinga University, Naya Raipur Chhattisgarh, India,
[2]Department of Civil Engineering, Structural Engineering, concrete technology, transportation, GIS and remote sensing, sustainable materials, smart infrastructure using IoT, Kalinga University, Naya Raipur Chhattisgarh, India
[3]Department of Civil Engineering,Environmental Engineering, concrete technology, transportation, gis and remote sensing, sustainable materials, smart infrastructure using IoT, Kalinga University, Naya Raipur Chhattisgarh,India

ku.honeygaur@kalingauniversity.ac.in[1]
ku.akshitlamba@kalingauniversity.ac.in[2]
ku.swatiagrawal@kalingauniversity.ac.in[3]

Abstract: The possibility of applying the concept of Artificial Intelligence (AI) and robotics in pharmaceutical production can transform the speed, precision, and capacity of the latter, yet it is also associated with significant legal, commercial, and engineering concerns. In this work, the author examines the specified issues through a mixed-method study that involves both a secondary analysis of 50 peer-reviewed articles and industry reports as well as primary research of 15 interviews with experts. Key findings have that the largest amounts of companies are a subject to the 72-percentage liability most important legal issue, 63 and 55 percent liability and data privacy, respectively. Critical barriers in business sphere are high capital investment (reported by 78% of the respondents) and workforce adaptation (65%), and work with 58% of the organizations that have issues with strategic alignment. Engineering concerns, namely, system integration, robustness and cybersecurity, scored well with an average impact mark of 4.2 and 4.3 on a 5-point scale. The study also mentions interdependence of domains because the losses and legal violations occur in domains where the cybersecurity is not effective, which explains why it should be taken as a whole. Accepted mitigation measures are consolidated regulatory frameworks, gradual investment strategy, reskilling of employees and high-technology engineering defence.Altogether, the study offers practical recommendations that pharmaceutical companies should use to implement AI and robotics in a responsible way, streamline the processes, and become more innovative and reduce risks.

Keywords: Artificial Intelligence, Robotics, Pharmaceutical Manufacturing, Legal Challenges, Engineering Challenges

I. INTRODUCTION

The pharmaceutical industry is witnessing a transformative shift with the introduction of AI and robotics into the manufacturing process to improve efficiency, accuracy, and scalability. With global demand for pharmaceutical products growing, there is a need for pharmaceutical companies to leverage novel technologies while maintaining strict quality measures [1]. AI-based systems can be used to optimize drug formulation, predict when a production bottleneck will occur, and control quality in real time, whereas robotics can automate repetitive and dangerous tasks eliminating human error and protecting workers [2]. Overall, these two technologies will help transformed pharmaceutical manufacturing by reducing time to market, lowering cost, and ensuring product quality is consistent.

Although the advantages are very clear, there are major challenges associated with the implementation of AI and robotics in pharmaceutical manufacturing in both legal, business, and engineering spheres. In legal terms pharmaceutical companies must be confined to intertwined regulatory systems to ensure that they are in compliance with international laws such as the

FDA, EMA and other regulatory authorities [3]. Technical legal matters such as the liability, the intellectual property and privacy of data complicate the situation. At the corporate level, the implementation of AI and robotics will demand a colossal capital and staff training and planning to achieve the organizational goal. The consideration the companies should make include the workforce dynamic implications, the supply chain management, and the competitive positioning, as well. Other significant engineering issues include design, validation, and maintenance of AI and robotic systems to function and perform in a highly controlled pharmaceutical environment. System robustness, cybersecurity, interoperability and real-time data integration have been the key to the smooth implementation.

The paper will be intended to elaborate on the complex issues of AI and robotics application in the pharmaceutical production. The study aims to enlighten the stakeholders of the risks that may arise and the solutions to the strategic challenges by evaluating the legal, business, and engineering viewpoint and emerge more successful and responsible in the process of integration of these transformational technologies in the pharmaceutical industry.

II. RELATED WORKS

Artificial Intelligence (AI) and robotics have become the trend in any industry, including medical services, drug production, and enterprise administration, which can now be considered as an environment of efficiency, innovation and sustainability.The recent researches prove that AI-powered technologies are potentially evolutionary, simultaneously pointing out the concerns to which utilization of said technologies was assigned.

In particular, AI-value wearable bioelectronics to enhance patient monitoring and digital medical care has begun to highlight the potential that is inherent with AI-driven medical care in enhancing the accuracy of diagnosis and treatment outcomes [15].The role of AI in healthcare systems has also been taken into account in several studies, which identified the obstacles and enabling factors to adopt the technology. Hassan et al. [18], has carried out a scoping review with an evaluation of the systemic barriers and technology barriers and ethical barriers influencing the adoption of AI and the necessity of the formulated structured governance and training of possible adoption AI-driven bioelectronics. Smart hospital prototyping Anticipatory studies demonstrated how AI in most settings can facilitate operational efficiency and patient care by using predictive analytics, and real-time monitoring capabilities [20].

Besides the healthcare industry, there has been increased application of AI in business in an innovative and sustainable manner. Guanyan and Bingxiang [16] investigated how AI promotes green collaborative innovation through high-dimensional empirical models and found that AI has the ability to optimize resources and promote a sustainable industrial process. Similarly, the contribution of AI to management accounting and the society has also been discussed and it demonstrates how AI tools boost decision making process, risk evaluation and efficiency in operations [21]. In addition to that, AI has been adopted in service innovation and business development in special economic zones, including the Hainan Free Trade Port, where the application of AI will help not only in legal but in business development as well [25]. Convergence Technologically speaking, research has revealed that AI technologies are slowly coming together in a network with other emerging technologies to drive innovation in the health sector [17]. The findings of the present paper demonstrate the importance of seeing the interdisciplinary character of AI adoption, i.e. the technical, regulatory and operational dimensions of the given issue. The construction industry, management of urban buildings also

make use of AI-based methods, and this case also represents cross-domain possibilities of AI and the problems of complex systems integration [19].

The elements of law and ethics have also been on the frontline in the recent literature. The crossroads of AI and international trade law and fiduciary have raised questions of accountability, liability and governance [22,26]. The efforts to build international data-driven solutions and AI governance systems are essential so as to ensure AI deployment is coordinated with the human rights and sustainability objectives [23]. In addition, a methodical review of the publicly accessible healthcare services, e.g., Saudi Arabia, shows the most prominent success factors to be applied AI, i.e., emphasis on policy frameworks, the preparedness of the infrastructure, and the involvement of stakeholders [24].

Collectively, these works indicate that although AI and robotics have the potential to bring disruptive opportunities to the business, manufacturing, and healthcare sector, they raise difficult issues associated with legal compliance, technological implementation, and organizational preparedness. The literature has emphasised the need to adopt interdisciplinary solutions that at once consider both the possible advantages and the possible harms of AI and robotic technologies; so that the people will be able to devise frameworks that would allow the responsible use of robotic and AI tools.

III. METHODS AND MATERIALS

In the proposed research, the mixed-methods research design will be applied to determine the multidimensional nature of the issues related to the application of Artificial Intelligence (AI) and robotics in pharmaceutical manufacturing. The methodology will be geared towards providing a detailed perspective of the legal, business and engineering concerns in accordance with the combination of qualitative data with quantitative analysis [3]. The research design will be formulated in the manner that it will collect, analyze, and report data systematically through different sources to determine reliability and validity of findings.

3.1 Research Design

The study employed descriptive and exploratory research design in the study, which is appropriate in cases where the researcher aims at investigating complex phenomena in an actual life scenario. The current challenges and practices in AI and robotic integration can be identified and recorded with the help of the descriptive one and the new trends, risks, and potential solutions can be disclosed with the help of the exploratory one [4]. The two-sided approach will not only chart the current scenario but also forecast the future.

3.2 Data Collection Methods

The information shall be gathered based on the secondary sources of data and primary interviews:

1. **Secondary Data**: It shall include peer-reviewed journal articles, regulatory documents and industry reports and white papers released no earlier than five years ago. The mentioned sources provide information about technological trends, the legal framework, business strategies, and engineering solutions of the pharmaceutical production. Key databases such as Scopus, PubMed, IEEE Xplore and Google Scholar were used to acquire the corresponding literature [5].
2. **Primary Data:** 15 industry professionals (regulatory professionals, process engineers, AI professionals and pharmaceutical executives) were interviewed through semi-structured analysis. The issues, experience, and successful implementation of AI and robotics were

the subject of the interviews. The interview queries were designed to respond to legal compliance, business integration and feasibility of engineering.

Table 1: Summary of Data Sources

Data Type	Source/Method	Purpose	Number/Range
Secondary Data	Journal articles, reports, white papers	To review existing literature and industry trends	50 articles/reports
Primary Data	Semi-structured interviews	To gather expert opinions and practical insights	15 experts

3.3 Research Philosophy and Approach

The study relies on the interpretivism research philosophy that is aimed at the understanding of the multifaceted socio-technology interactions between human beings, AI and robotics in the pharmaceutical production process. The study is deductive in nature and this is where theoretical concepts and available literature are used to form assumptions on problems and solutions [6].

3.4 Sampling Strategy

Primary method of data collection used was purposive sampling method. The professionals have been selected based on their work experience in pharmaceutical production, AI implementation, and regulatory framework. In such a manner the gathered information becomes very local and immediate.

3.5 Data Analysis Methods

These are the two approaches that integrate qualitative thematic and quantitative trend analysis: Data analysis:

- **Qualitative Analysis**: NVivo software was utilized in the conduct of the qualitative analysis of transcripts of the interviews. Themes about legal, business and engineering issues were found, coded and categorized to generate meaningful insights [7]. The thematic analysis helped in aiding the nuances that cannot be given by the secondary data.
- **Quantitative Analysis:**The descriptive statistics have been used to analyse the Secondary data on the technology adoption, cost impact and the rates of compliance to regulations. It was identified that trends could be used to quantify the extent of AI and robotics integration and issues surrounding it.

Table 2: Data Analysis Framework

Analysis Type	Tool/Method	Purpose
Qualitative	NVivo thematic coding	Identify recurring themes and expert opinions
Quantitative	Descriptive statistics	Analyze adoption trends, cost, and compliance rates

3.6 Ethical Considerations

The research on ethical compliance was valuable. For interviews, informed consent was gained from all participants, confidentiality and anonymity were guaranteed, and the data was kept securely in accordance with ethical guidelines. Participants were made aware of the data storage and there were opportunities for participants to withdraw from the study process at any stage. All secondary sources were properly cited to ensure no plagiarism occurred [8].

3.7 Limitations of the Methodology

This methodology represents a holistic perspective, but it is not without limitations. The use of secondary data means that there may be publication bias that needs to be confirmed by primary research, and the size of the sample in the interviews is small, which cannot cover all possible perspectives. However, the use of the quantitative study and qualitative interviews allow for a set of limitations to be counterbalanced by the other [9]. Triangulation increases confidence in findings through both quantitative study and qualitative research, as well as cross-validation of findings.

IV. RESULTS AND ANALYSIS

4.1 Legal Challenges

The legal and regulatory environment of applying AI and robotics in pharmaceutical manufacturing is a cumbersome issue. A review of the secondary sources and interviews with teachers revealed three key themes, i.e., regulation compliance, and the issue of liability and responsibility, and information privacy/intellectual property [10].

1. **Regulatory Compliance**: Experts stated that artificial intelligence practices and robotics must correspond to the rigid regulatory standards, such as FDA 21 CFR Part 11, EMA regulations, and Good Manufacturing Practices (GMP). AI systems are dynamic, and validation and documentation needs are more difficult due to the fact that self-learning algorithms are dynamic.
2. **Liability and Accountability:** it is complicated to determine the liabilities in cases of error committed by AI or malfunctioning robots. One such situation is when a robotic system is filling doses wrongly and the AI has not made the right judgment with regards to a formulation, the legal responsibility can be ascribed to the manufacturers, creators or operators [11].

3. **Data privacy and Intellectual Property:** AI systems will require access to huge data, including proprietary formulations and patient related data. There is a strong necessity to make sure that GDPR, HIPAA, and other laws on data protection are followed. In addition, intellectual property rights concerning AI-Generated formulations are not legally clear.

Figure 1: "Role of Artificial Intelligence (AI) in The Pharmaceutical Industry"

Table 1: Summary of Legal Challenges

Challenge Type	**Key Issues Identified**	**Frequency in Interviews**	**References**
Regulatory Compliance	Validation, documentation, evolving guidelines	12/15	[1, 2,5]
Liability and Accountability	System errors, unclear responsibility	10/15	[2, 3,6]
Data Privacy & IP	Data breaches, AI-generated IP ambiguity	8/15	[4, 5,7]

Secondary sources were quantitatively analyzed to show that 72 percent of pharmaceutical firms mentioned regulatory compliance as the first obstacle to AI integration, then came the concern of

liability (63 percent) and data privacy concerns (55 percent). This highlights how critical harmonization of the regulatory frameworks and risk mitigation measures are.



Figure 2: "Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design"

4.2 Business Challenges

On the business side, the implementation of AI and robotics would require the large financial expenditure, restructuring of the workforce and a redefinition of strategy. The following were identified as key challenges in interviews:

1. **Capital Investment**: The greatest barrier was found to be high costs related to procuring, implementing, and maintaining AI and robotic systems. Medium-sized pharmaceutical companies and start-ups have large resource limitations [12].
2. **Adaptation of the workforce:** To operate, monitor and maintain AI-robotic systems employees need to be reskilled. Another common theme was resistance to change with fear of job loss being a frequent theme during interviews.
3. **Strategic Alignment:** Companies must align AI and robotics to their business model and take into account the processes of supply chain management, competitive positioning, and operational efficiency. Inability to align technology adoption and business objectives can lower ROI and decelerate adoption [13].

Table 2: Business Challenges in AI & Robotics Adoption

Challenge Type	Key Issues Identified	Frequency in Interviews	Quantitative Data (%)
Capital	High costs, ROI	13/15	78

Investment	uncertainty		
Workforce Adaptation	Reskilling, resistance, job displacement	11/15	65
Strategic Alignment	Supply chain integration, operational ROI	10/15	58

The analysis of secondary data showed that the companies that invested over 10 million in AI-robotic integration cited more efficiency gains and a lower error rate by 30-40 percent than companies that invested less. It is showing that financial commitment is positively correlated with operational results.

4.3 Engineering Challenges

Engineering issues became one of the important aspects influencing the implementation of AI and robotics. Three major themes that were identified in the study are system design and integration, robustness and reliability and cybersecurity and data integration.

1. **System Design and Integration**: It can be difficult to interoperate AI algorithms and robotic systems with current manufacturing lines, as well as to calibrate and maintain them. Tailor-made solutions may be necessary to fit in particular pharmaceutical processes.
2. **Strength and Consistency:** AI and robotics have to perform in high-precision conditions and with high consistency. Malady, bugs in the software or a hardware malfunction can cause huge losses in production [14].
3. **Cybersecurity and Data Integration:** Data and AI-robotic systems are prone to cyberattacks, which jeopardize the disruption of production and theft of data. It is necessary to confirm secure real-time integration with manufacturing execution systems (MES) and enterprise resource planning (ERP) systems.

Table 3: Engineering Challenges

Challenge Type	**Key Issues Identified**	**Frequency in Interviews**	**Impact Score (1–5)**
System Design & Integrati	Interoperability, calibration, custom	12/15	4.2

on	adaptation		
Robustness & Reliability	Software bugs, hardware failures	10/15	4.0
Cybersecurity & Data	Hacking risk, secure data integration	11/15	4.3

Analysis of secondary data revealed that the majority of production delays in AI-robotic systems were associated with failure in the system integration, which is why it is necessary to present stringent testing, simulation, and validation procedures.



Figure 3: "Innovative Robotic Technologies and Artificial Intelligence in Pharmacy and Medicine"

4.4 Cross-Domain Comparative Analysis

The study also conducted a comparative study of legal, business, and engineering issues in order to detect overlapping risks and interdependencies. A summary of the challenge severity and prevalence in the three domains is summarized in Table 4.

Table 4: Comparative Analysis of Challenges

Domain	**Most Prevalent Challenge**	**Secondary Challenge**	**Severity (1–5)**
Legal	Regulatory compliance	Liability & Accountability	4.5
Business	Capital investment	Workforce adaptation	4.3
Engineering	Cybersecurity & Data Integration	System Integration	4.2

This comparison shows that the three aspects are all challenging, but legal adherence and cybersecurity are the most important indicators of effective AI-robotic implementation in pharmaceutical production [27].

4.5 Mitigation Strategies Identified

In interviews and a literature review, specialists suggested a few mitigation measures:

1. **Legal Domain**: Standardizing regulatory frameworks of AI-driven processes, explicit liability principles and organized IP policy.
2. **Business Area:** Step-by-step investment strategies, on-going training of employees, and adapting AI implementation to business strategies [28].
3. **Domain of Engineering:** Stringent testing of systems, overlapping of systems in critical processes and incorporation of more advanced cybersecurity measures such as AI driven threat detection [29].

Table 5: Mitigation Strategies for Key Challenges

Domain	Challenge	Mitigation Strategy
Legal	Regulatory Compliance	Standardized frameworks, continuous regulatory updates
Business	Capital Investment	Phased implementation, cost-benefit analysis
Engineering	Cybersecurity & Data	AI-based threat monitoring, secure integration protocols

These suggestions offer actionable routes for pharmaceutical companies who want to balance technological innovation against compliance and cost/operational safety.



Figure 4: "Innovative Robotic Technologies and Artificial Intelligence in Pharmacy and Medicine"

4.6 Discussion of Key Findings

The conclusions are that AI and Robotics are certainly good on larger efficiencies in the production of pharmaceuticals, but they are also marked by burdensome legal, business, and engineering challenges.

The regulatory compliance and the liability elements that are conducive to the legal sphere are very restrictive and can delay the implementation process unless considered initially and in a proactive way [30]. With regard to the presentation of the business, small and medium-sized businesses still have obstacles to economic viability and adjustment of personnel. The technical problems that need effective technical solutions to enable operations are technical barriers and these include the engineering barriers, which include systems integration and cybersecurity.

V. CONCLUSION

This paper has illustrated a complex discussion of the multi-faceted issues surrounding the application of the Artificial Intelligence (AI) and robotics in the pharmaceutical manufacturing industry. This evidence demonstrates that, although the potential to increase efficiency, accuracy and scale of drug production with the help of AI and robotics are immense, its application is limited by legal, business and engineering-related issues. The major barriers that need to be reconciled and be ready with the clear accountability practices under the law are the regulatory compliance, liability, data privacy and intellectual property.

The barriers related to the business such as the high capital investment level, human resources, and alignment of the strategy make it apparent that the preparations of the organization, stepwise implementation strategy, and additional training of the personnel would be required. The need to perform proper testing, verification activities and secure data handling measures are explained by both the engineering challenges, especially, by the system integration elements, its stability, reliability and its cyber protection.

The study also discovered that these problems tend to be interconnected; the violation of regulations and financial losses can occur in case of ineffective cybersecurity systems and, that is why the comprehensive approach is significant. The suggested mitigation measures out of the interviews and literature analysis provide feasible mitigation measures which are standardization of the regulation strategy, AI-governance models, periodic investment plans, reskilling of the staff, and innovative engineering controls. In general, the research contributes to the fact that the successful introduction of AI and robotics to the sphere of pharmaceutical production preconditions the interdisciplinary collaboration of the legal community, business strategists, and engineering practitioners.

REFERENCE

[1]Agarwal, P., Swami, S. & Sunita, K.M. 2024, "Artificial Intelligence Adoption in the Post COVID-19 New-Normal and Role of Smart Technologies in Transforming Business: a Review", *Journal of Science and Technology Policy Management*, vol. 15, no. 3, pp. 506-529.

[2]Ali, T., Husam, Y., Alsoud, M.A., Al-Salim, M. & Hattar, C. 2025, "Empowering Startup Supply Chain: Exploring the Integration of SCF, AI, Blockchain, and Trust", *Logistics*, vol. 9, no. 2, pp. 69.

[3]Alshahrani, S.T., Jamel, C., Saja, A. & AlShalhoob, A.A. 2025, "Perceptions of the Impact of AI on Human Resource Management Practices Among Human Resource Managers Working in the Chemical Industry in Saudi Arabia", *Sustainability*, vol. 17, no. 13, pp. 5815.

[4]Al-Talib, M., Al-Saad, W., Alzoubi, A. & Anosike, A.I. 2025, "A systematic review of the literature on the use of information technologies in supply chain management", *International Journal of Industrial Engineering and Operations Management*, vol. 7, no. 3, pp. 247.
[5]Al-Talib, M., Al-Saad, W., Alzoubi, A. & Anosike, A.I. 2025, "A systematic review of the literature on the use of information technologies in supply chain management", *International Journal of Industrial Engineering and Operations Management*, vol. 7, no. 3, pp. 247.
[6]Angelina, Q., Khadija, B., Hee-Cheol, K., Sushanta, T., Deepak, S. & Saranjit, S. 2025, "A Structural Analysis of AI Implementation Challenges in Healthcare", *Algorithms*, vol. 18, no. 4, pp. 189.
[7]Antreas, K., Christos, D., Michail, P., Evangelos, P. & Theodore, G. 2025, "The Role of 3D Printing in Advancing Automated Manufacturing Systems: Opportunities and Challenges", *Automation*, vol. 6, no. 2, pp. 21.
[8]Benbya, H., Strich, F. & Tamm, T. 2024, "Navigating Generative Artificial Intelligence Promises and Perils for Knowledge and Creative Work", *Journal of the Association for Information Systems*, vol. 25, no. 1, pp. 23-36.
[9]Calzada, I., Németh, G. & Mohammed Salah Al-Radhi 2025, "Trustworthy AI for Whom? GenAI Detection Techniques of Trust Through Decentralized Web3 Ecosystems", *Big Data and Cognitive Computing*, vol. 9, no. 3, pp. 62.
[10]Chen, R. & Chen, Y. 2024, "Optimizing Digital Market Decision-Making Through Artificial Intelligence Platforms: Governing Mediating Powers of Cognitive Engagement", *Journal of Global Information Management*, vol. 32, no. 1, pp. 1-27.
[11]El-Gohary, H., Mohamed, B.M. & Ahmad, A. 2025, "Examining the Spectrum of Artificial Intelligence Failures: A Focus on Users' Point of View", *International Journal of Customer Relationship Marketing and Management*, vol. 16, no. 1, pp. 1-21.
[12]Espina-Romero, L., Humberto Gutiérrez Hurtado, Doile Ríos Parra, Rafael Alberto, V.P., Talavera-Aguirre, R. & Ochoa-Díaz, A. 2024, "Challenges and Opportunities in the Implementation of AI in Manufacturing: A Bibliometric Analysis", *Sci*, vol. 6, no. 4, pp. 60.
[13]Faiyazuddin, M., Rahman, S.J.Q., Anand, G., Siddiqui, R.K., Mehta, R., Khatib, M.N., Gaidhane, S., Zahiruddin, Q.S., Hussain, A. & Sah, R. 2025, "The Impact of Artificial Intelligence on Healthcare: A Comprehensive Review of Advancements in Diagnostics, Treatment, and Operational Efficiency", *Health Science Reports*, vol. 8, no. 1.
[14]Fujiang, Y., Zihao, Z., Jiang, Y., Wenzhou, S., Zhen, T., Chenxi, Y., Yang, J., Zebing, M., Huang, X., Shaojie, G. & Yanhong, P. 2025, "AI-Driven Optimization of Blockchain Scalability, Security, and Privacy Protection", *Algorithms*, vol. 18, no. 5, pp. 263.
[15]Guangqi, H., Chen, X. & Caizhi, L. 2025, "AI-Driven Wearable Bioelectronics in Digital Healthcare", *Biosensors*, vol. 15, no. 7, pp. 410.
[16]Guanyan, L. & Bingxiang, L. 2025, "Artificial Intelligence and Green Collaborative Innovation: An Empirical Investigation Based on a High-Dimensional Fixed Effects Model", *Sustainability*, vol. 17, no. 9, pp. 4141.
[17]Guo, X., Miao, H. & Huang, L. 2025, "Research on Technology Convergence and Innovation Facing the Health Industry: A Review", *Pacific Asia Journal of the Association for Information Systems*, vol. 17, no. 3, pp. 39.
[18]Hassan, M., Kushniruk, A. & Borycki, E. 2024, "Barriers to and Facilitators of Artificial Intelligence Adoption in Health Care: Scoping Review", *JMIR Human Factors*, vol. 11.

[19]Ivanova, S., Kuznetsov, A., Zverev, R. & Rada, A. 2023, "Artificial Intelligence Methods for the Construction and Management of Buildings", *Sensors,* vol. 23, no. 21, pp. 8740.
[20]Jovy-Klein, F., Stead, S., Torsten, O.S., Sander, J., Diehl, A. & Antons, D. 2024, "Forecasting the future of smart hospitals: findings from a real-time delphi study", *BMC Health Services Research,* vol. 24, pp. 1-21.
[21]Kerr, D., Smith, K.T., Smith, L.M. & Xu, T. 2025, "A Review of AI and Its Impact on Management Accounting and Society", *Journal of Risk and Financial Management,* vol. 18, no. 6, pp. 340.
[22]Khan, A. 2024, "THE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND INTERNATIONAL TRADE LAWS: CHALLENGES AND OPPORTUNITIES", *IIUM Law Journal,* vol. 32, no. 1, pp. 103-152.
[23]Kirchschlaeger, P.G. 2024, "An International Data-Based Systems Agency IDA: Striving for a Peaceful, Sustainable, and Human Rights-Based Future", *Philosophies,* vol. 9, no. 3, pp. 73.
[24]Kumar, R., Singh, A., Subahi, A., Humaida, M., Joshi, S. & Sharma, M. 2025, "Leveraging Artificial Intelligence to Achieve Sustainable Public Healthcare Services in Saudi Arabia: A Systematic Literature Review of Critical Success Factors", *Computer Modeling in Engineering & Sciences,* vol. 142, no. 2, pp. 1289-1349.
[25]Li, Y., Wang, S. & Khaskheli, M.B. 2024, "Integrating Artificial Intelligence into Service Innovation, Business Development, and Legal Compliance: Insights from the Hainan Free Trade Port Era", *Systems,* vol. 12, no. 11, pp. 463.
[26]Li, Z. 2024, "Artificial Fiduciaries", *Washington and Lee Law Review,* vol. 81, no. 4, pp. 1299-1378,1299A.
[27]Licardo, J.T., Domjan, M. & Orehovački, T. 2024, "Intelligent Robotics—A Systematic Review of Emerging Technologies and Trends", *Electronics,* vol. 13, no. 3, pp. 542.
[28]Marino, A., Pariso, P. & Picariello, M. 2022, "Transition towards the artificial intelligence via re-engineering of digital platforms: comparing European Member States", *Entrepreneurship and Sustainability Issues,* vol. 9, no. 3, pp. 350-368.
[29]Minahil, K., Zhang, C., Shalahudin, M., Hitesh, K., Kimi, A., Kalana, A., Utkarsh, C. & Kamran, B. 2025, "Artificial Intelligence in Manufacturing Industry Worker Safety: A New Paradigm for Hazard Prevention and Mitigation", *Processes,* vol. 13, no. 5, pp. 1312.
[30]Mohammad Rashed, H.P., Asghar, A.J., Kabir, A.I., Abu Saleh Md Sohel-Uz-Zaman, Abu, R.O. & Karim, R. 2022, "Artificial Intelligence, Blockchain Technology, and Risk-Taking Behavior in the 4.0IR Metaverse Era: Evidence from Bangladesh-Based SMEs", *Journal of Open Innovation : Technology, Market, and Complexity,* vol. 8, no. 3, pp. 168.